来自官方财务报表的收入、利润与现金流历史。
波士顿科学公司开发、制造和销售用于全球各种介入医学专业的医疗设备。该公司经营两个部门：医疗外科和心血管部门。该公司提供诊断和治疗一系列胃肠道疾病的设备，例如分辨率夹、胆管支架系统、支架和电灼增强输送系统、SpyGlass、用于胰胆系统诊断和治疗程序、内窥镜逆行胰胆管造影程序和一次性十二指肠镜的一次性示波器，以及腔内手术和感染预防产品；治疗泌尿系统疾病的设备，包括输尿管支架、导管、篮子、导丝、泌尿和肠道功能障碍、鞘管、球囊、一次性数字输尿管软镜、钬激光系统、阴茎植入物、人工尿道括约肌、激光系统和水凝胶系统；以及治疗神经运动障碍和控制慢性疼痛的设备，例如脊髓刺激器系统、射频消融、骨内神经消融和深部脑刺激系统。该公司还提供诊断和治疗一系列心脏疾病和异常的技术； WATCHMAN FLX，一种左心耳封堵器 (LAAC) 装置；监测心脏并提供电力以治疗心脏异常的植入式设备，例如心脏复律和心脏再同步治疗除颤器、MRI S-ICD 系统、心脏再同步治疗起搏器、远程患者管理系统、可插入心脏监护系统和远程心脏监护系统。此外，它还提供心率和节律紊乱的诊断和治疗；周边
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $21.0B | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B | $9.9B | $10.7B | $9.8B | $9.0B | $8.4B | $7.5B | $7.4B | $7.1B | $7.2B | $7.6B | $7.8B | $8.2B | $8.1B | $8.4B | $7.8B |
| 毛利 | $14.9B | $13.9B | $10.3B | $8.8B | $7.7B | $7.5B | $5.6B | $6.9B | $6.5B | $5.9B | $5.3B | $4.6B | $4.6B | $4.5B | $4.6B | $4.7B | $4.8B | $5.2B | $5.1B | $5.4B | $5.1B |
| 毛利率% | 71.2% | 69.0% | 61.3% | 62.0% | 60.8% | 62.8% | 56.2% | 64.1% | 65.9% | 64.9% | 63.7% | 61.0% | 62.2% | 63.5% | 62.9% | 61.4% | 61.3% | 63.2% | 63.2% | 64.6% | 65.0% |
| 营业利润（EBIT） | $4.5B | $4.0B | $2.6B | $2.2B | $1.8B | $1.9B | $601M | $1.7B | $1.7B | $1.5B | $1.2B | $790M | $845M | $871M | $994M | $1.1B | $1.1B | $1.3B | $1.3B | $1.2B | $1.2B |
| 营业利润率% | 21.5% | 19.8% | 15.7% | 15.3% | 14.4% | 16.2% | 6.1% | 16.0% | 17.7% | 16.9% | 14.7% | 10.6% | 11.5% | 12.2% | 13.7% | 14.7% | 13.8% | 15.9% | 16.1% | 14.1% | 15.8% |
| 净利 | $3.7B | $2.9B | $1.9B | $1.6B | $698M | $1.0B | ($82M) | $4.7B | $1.7B | $104M | $347M | ($239M) | ($119M) | ($121M) | ($4.1B) | $441M | ($1.1B) | ($1.0B) | ($2.0B) | ($495M) | ($3.6B) |
| 净利润率 % | 17.5% | 14.4% | 11.1% | 11.2% | 5.5% | 8.8% | -0.8% | 43.8% | 17.0% | 1.1% | 4.1% | -3.2% | -1.6% | -1.7% | -56.1% | 5.8% | -13.6% | -12.5% | -25.3% | -5.9% | -45.7% |
| EBITDA | $5.5B | $5.1B | $3.9B | $3.5B | $2.7B | $2.5B | $1.5B | $2.2B | $2.6B | $2.0B | $1.2B | $360M | $433M | $721M | ($3.2B) | $1.6B | $149M | ($108M) | ($699M) | $940M | ($2.3B) |
| 每股收益（EPS） | $2.46 | $1.93 | $1.25 | $1.09 | $0.48 | $0.73 | $-0.06 | $3.33 | $1.19 | $0.07 | $0.25 | $-0.18 | $-0.09 | $-0.09 | $-2.89 | $0.29 | $-0.70 | $-0.68 | $-1.36 | $-0.33 | $-2.81 |
| 已发行股数 (M) | 1,485M | 1,494M | 1,486M | 1,464M | 1,440M | 1,434M | 1,417M | 1,411M | 1,401M | 1,393M | 1,377M | 1,341M | 1,348M | 1,341M | 1,407M | 1,519M | 1,518M | 1,508M | 1,498M | 1,487M | 1,274M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 BSX 交互式查看器。 /companies/us/BSX
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms